These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
262 related articles for article (PubMed ID: 21917149)
21. Cells with characteristics of cancer stem/progenitor cells express the CD133 antigen in human endometrial tumors. Rutella S; Bonanno G; Procoli A; Mariotti A; Corallo M; Prisco MG; Eramo A; Napoletano C; Gallo D; Perillo A; Nuti M; Pierelli L; Testa U; Scambia G; Ferrandina G Clin Cancer Res; 2009 Jul; 15(13):4299-311. PubMed ID: 19509143 [TBL] [Abstract][Full Text] [Related]
22. [Investigation of CD133 as putative marker of tumor-initiating cell in laryngeal carcinoma]. Wei XD; Zhou L; Cheng L; Tian J Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2007 Sep; 42(9):692-6. PubMed ID: 18051573 [TBL] [Abstract][Full Text] [Related]
23. Subpopulation of small-cell lung cancer cells expressing CD133 and CD87 show resistance to chemotherapy. Kubo T; Takigawa N; Osawa M; Harada D; Ninomiya T; Ochi N; Ichihara E; Yamane H; Tanimoto M; Kiura K Cancer Sci; 2013 Jan; 104(1):78-84. PubMed ID: 23066953 [TBL] [Abstract][Full Text] [Related]
24. The role of CD133 expression in the carcinogenesis and prognosis of patients with lung cancer. Le H; Zeng F; Xu L; Liu X; Huang Y Mol Med Rep; 2013 Nov; 8(5):1511-8. PubMed ID: 24008862 [TBL] [Abstract][Full Text] [Related]
25. CD133+, CD166+CD44+, and CD24+CD44+ phenotypes fail to reliably identify cell populations with cancer stem cell functional features in established human colorectal cancer cell lines. Muraro MG; Mele V; Däster S; Han J; Heberer M; Cesare Spagnoli G; Iezzi G Stem Cells Transl Med; 2012 Aug; 1(8):592-603. PubMed ID: 23197865 [TBL] [Abstract][Full Text] [Related]
26. Isolation, characterization and mobilization of prostate cancer tissue derived CD133+ MDR1+ cells. Rentala S; Mangamoori LN J Stem Cells; 2010; 5(2):75-81. PubMed ID: 22049617 [TBL] [Abstract][Full Text] [Related]
27. CD133 expression in chemo-resistant Ewing sarcoma cells. Jiang X; Gwye Y; Russell D; Cao C; Douglas D; Hung L; Kovar H; Triche TJ; Lawlor ER BMC Cancer; 2010 Mar; 10():116. PubMed ID: 20346143 [TBL] [Abstract][Full Text] [Related]
28. Minnelide effectively eliminates CD133(+) side population in pancreatic cancer. Nomura A; McGinn O; Dudeja V; Sangwan V; Saluja AK; Banerjee S Mol Cancer; 2015 Nov; 14():200. PubMed ID: 26597727 [TBL] [Abstract][Full Text] [Related]
29. The role of CD133 in the identification and characterisation of tumour-initiating cells in non-small-cell lung cancer. Tirino V; Camerlingo R; Franco R; Malanga D; La Rocca A; Viglietto G; Rocco G; Pirozzi G Eur J Cardiothorac Surg; 2009 Sep; 36(3):446-53. PubMed ID: 19464919 [TBL] [Abstract][Full Text] [Related]
30. Dysplasia of human prostate CD133(hi) sub-population in NOD-SCIDS is blocked by c-myc anti-sense. Goodyear SM; Amatangelo MD; Stearns ME Prostate; 2009 May; 69(7):689-98. PubMed ID: 19143028 [TBL] [Abstract][Full Text] [Related]
31. Aldehyde dehydrogenase discriminates the CD133 liver cancer stem cell populations. Ma S; Chan KW; Lee TK; Tang KH; Wo JY; Zheng BJ; Guan XY Mol Cancer Res; 2008 Jul; 6(7):1146-53. PubMed ID: 18644979 [TBL] [Abstract][Full Text] [Related]
32. Acquisition of tumorigenic potential and therapeutic resistance in CD133+ subpopulation of prostate cancer cells exhibiting stem-cell like characteristics. Kanwal R; Shukla S; Walker E; Gupta S Cancer Lett; 2018 Aug; 430():25-33. PubMed ID: 29775627 [TBL] [Abstract][Full Text] [Related]
33. Flow cytometric characterization of the DAOY medulloblastoma cell line for the cancer stem-like phenotype. Srivastava VK; Nalbantoglu J Cytometry A; 2008 Oct; 73(10):940-8. PubMed ID: 18773455 [TBL] [Abstract][Full Text] [Related]
34. In vitro identification and characterization of CD133(pos) cancer stem-like cells in anaplastic thyroid carcinoma cell lines. Zito G; Richiusa P; Bommarito A; Carissimi E; Russo L; Coppola A; Zerilli M; Rodolico V; Criscimanna A; Amato M; Pizzolanti G; Galluzzo A; Giordano C PLoS One; 2008; 3(10):e3544. PubMed ID: 18958156 [TBL] [Abstract][Full Text] [Related]
35. CD133 expression is not selective for tumor-initiating or radioresistant cell populations in the CRC cell lines HCT-116. Dittfeld C; Dietrich A; Peickert S; Hering S; Baumann M; Grade M; Ried T; Kunz-Schughart LA Radiother Oncol; 2009 Sep; 92(3):353-61. PubMed ID: 19699546 [TBL] [Abstract][Full Text] [Related]
36. Molecular characterization of CD133+ cancer stem-like cells in endometrial cancer. Nakamura M; Zhang X; Mizumoto Y; Maida Y; Bono Y; Takakura M; Kyo S Int J Oncol; 2014 Mar; 44(3):669-77. PubMed ID: 24366104 [TBL] [Abstract][Full Text] [Related]
37. A rational approach for cancer stem-like cell isolation and characterization using CD44 and prominin-1(CD133) as selection markers. Lee YJ; Wu CC; Li JW; Ou CC; Hsu SC; Tseng HH; Kao MC; Liu JY Oncotarget; 2016 Nov; 7(48):78499-78515. PubMed ID: 27655682 [TBL] [Abstract][Full Text] [Related]
38. Isolation of cancer stem cells from transformed human mesenchymal stem cell line F6. Xu X; Qian H; Zhu W; Zhang X; Yan Y; Wang M; Xu W J Mol Med (Berl); 2010 Nov; 88(11):1181-90. PubMed ID: 20697686 [TBL] [Abstract][Full Text] [Related]
39. The stem cell marker CD133 associates with enhanced colony formation and cell motility in colorectal cancer. Elsaba TM; Martinez-Pomares L; Robins AR; Crook S; Seth R; Jackson D; McCart A; Silver AR; Tomlinson IP; Ilyas M PLoS One; 2010 May; 5(5):e10714. PubMed ID: 20502714 [TBL] [Abstract][Full Text] [Related]
40. CD133 is a temporary marker of cancer stem cells in small cell lung cancer, but not in non-small cell lung cancer. Cui F; Wang J; Chen D; Chen YJ Oncol Rep; 2011 Mar; 25(3):701-8. PubMed ID: 21174061 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]